Pathomics-based machine learning models for predicting METTL5 expression and prognosis in lung adenocarcinoma.
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: The primary full text supports the case-specific result: Pathomics models predicted METTL5 expression and prognosis in lung adenocarcinoma with validation performance.
Technology: Methods identify the case-specific learned operation: Pathomics models predicted METTL5 expression and prognosis in lung adenocarcinoma with validation performance.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Methods identify the case-specific learned operation: Pathomics models predicted METTL5 expression and prognosis in lung adenocarcinoma with validation performance.
- Limitation / still unknown
- The full text reports the case-specific data/cohort, comparison/reference and evaluation; no broader clinical benefit is inferred.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13559335/ · https://pubmed.ncbi.nlm.nih.gov/42724470/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.